AstraZeneca gout drug hits Phase III goal, but safety an issue

AstraZeneca's (AZN +2.3%) Lesinurad treatment for gout met the primary goal of a Phase III study, although it caused a number of side effects, some of which were serious.

The study tested Lesinurad for use in the small number of patients who are unable to take rival therapies allopurinol and febuxostat.

The side effects included increased levels of serum creatinine, which are an important indicator of renal health.

AstraZeneca is now waiting for the outcomes of three other Phase III trials, which are testing Lesinurad in combination with other drugs. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs